Results 171 to 180 of about 28,326 (256)

Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group

Early indicators of metastatic cancer response to therapy are important for evaluating new drugs and stopping ineffective treatment. The RECIST guidelines based on repeat cancer imaging are widely adopted in clinical trials, are used to identify active ...
Karlovich, CA, Seymour, L, Mateo, J, Schwartz, L, Tolmeijer, SH, Rothwell, D, Cabel, L, Alfano, C, Pantel, K, Petrie, J, The RECIST ctDNA workshop group, Bidard, FC, Attard, G, Rolfo, C, Alberu, XV, Garralda, E, Mizoguchi, C, Wyatt, AW, Bogaerts, J, Needham, J, Shankar, L, Alix-Panabières, C, Shaw, J, Calvo, E, Chen, AP, Dyrskjøt, L, Sudo, K, Tie, J, Toledo, RA, Laurie, SA, Ignatiadis, M, Philip, R, Yap, C, Ford, R, Parsons, H, Dancey, J, Andrews, HS, Williams, M, Stewart, M, De Vries, EGE, Vellanki, PJ, Mizusawa, J, Litiere, S   +42 more
core  

A High‐Sensitivity Circulating Nucleic Acid Sequencing Assay for Assessing Treatment Response to Alectinib in a Pediatric Patient With ALK‐Rearranged Non–Small Cell Lung Cancer

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
Alberto D. Guerra, Nicholas F. Evageliou, Vandana Batra, Kristen L. Dalton, Stephanie Ortel, Usman Ashraf, Tricia R. Bhatti, Lisa J. States, Lea F. Surrey, Theodore W. Laetsch   +9 more
wiley   +1 more source

Autophagy-Circulating Tumor DNA Axis in Molecular Cancer Research: Emerging Mechanisms, Therapeutic Targeting, and Translational Opportunities. [PDF]

Int J Mol Sci
Harrath AH, Jalouli M, Rahman MA.
europepmc   +1 more source

Tumor-derived cell-free DNA detected in cerebrospinal fluid enables minimally invasive profiling of pediatric brain tumors. [PDF]

J Clin Invest
Nobre L, Nakano Y, Burns I, Siddaway R, Zápotocky M, Johnson M, Rana M, Li C, Lyn RK, Yuditskiy R, Ku M, Sheth J, Levine AB, Nesvick CL, Das A, Cacciotti C, Zelcer S, Climans SA, MacDonald M, Negm L, Chung J, Bennett J, Bondoc A, Loukides J, Stengs L, Edwards M, Bouffet E, Ramaswamy V, Liu AP, Huang A, Bartels U, Dirks PB, Tabori U, Hawkins C.   +33 more
europepmc   +1 more source

Rezatapopt and the Return of Targetable p53

MedComm, Volume 7, Issue 7, July 2026.
Yuanze Luo, Assam El‐Osta
wiley   +1 more source

Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial. [PDF]

Clin Cancer Res
Valentín López JC, Yu C, Knutson TP, Kobilka A, Lyman J, Guo S, Luo B, Munro SA, Li Y, Heer R, Gaughan L, Morris MJ, Beltran H, Ryan CJ, Antonarakis ES, Armstrong AJ, Halabi S, Dehm SM.   +17 more
europepmc   +1 more source

Circulating Tumor DNA in Upper Tract Urothelial Carcinoma: A Framework for Precision Perioperative Management. [PDF]

Cancers (Basel)
Prakash A, Cherico A, Ayanambakkam A, Polimera HV.   +3 more
europepmc   +1 more source

Breaking the ctDNA sensitivity barrier

, 2017
O estudo da biologia molecular do cancro tem permitido avanços científicos com impacto na prática clínica, mudando o paradigma de abordagem terapêutica convencional, sistémica, para uma abordagem personalizada. No entanto, a caracterização molecular de tumores sólidos só é possível através da biopsia do tecido, uma estratégia altamente invasiva com ...
openaire   +1 more source

Development of an ligase chain reaction-fluorescence-SERS multimodal biosensing workflow for ultrasensitive detection and single-base discrimination of KRAS ctDNA. [PDF]

Mikrochim Acta
Mostafa S, Kanarya D, Tantiwanichapan K, Botta R, Eiamchai P, Somboonsaksri P, Yıldırım Tirgil N.   +6 more
europepmc   +1 more source

Circulating Tumor DNA as Emerging Predictive and Prognostic Biomarker in Prostate Cancer. [PDF]

Cancers (Basel)
Thapa B, Venturini J, Choudhury AD, Francini E.   +3 more
europepmc   +1 more source